This is a pre-planned sale under a 10b5-1 program with no urgent signal. Monitor the subsequent Form 4 filing to confirm execution. The small size relative to market cap suggests no material market impact.
QURE drugs
QURE drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 12 $27.57entry
- T+1 · 5mo ago +1.09%α −0.68% · $27.87
- T+5 · 5mo ago +67.90%α +67.23% · $46.29
- T+20 · 4mo ago +54.62%α +52.84% · $42.63
- T+60 · 2mo ago +65.69%α +62.42% · $45.68
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Director Balachandran Madhavan filed a Form 144 indicating intent to sell 11,993 ordinary shares of uniQure N.V. via Citigroup Global Markets, with an aggregate market value of approximately $324,578. The sale is tied to restricted stock unit vesting and a stock option exercise under a Rule 10b5-1 trading plan adopted on March 16, 2026. The transaction is small relative to the $1.7B market cap and appears routine.
Key Facts
- Director Balachandran Madhavan intends to sell 11,993 ordinary shares.
- Aggregate market value of proposed sale: $324,577.59.
- Sale includes 7,970 shares from RSU vesting and 10,000 shares from stock option exercise.
- The option exercise and sale are executed under a 10b5-1 plan adopted March 16, 2026.
- Filing date: June 11, 2026; broker: Citigroup Global Markets, Inc.
Financial Impact
Sale of 11,993 shares valued at ~$324,578, representing about 0.02% of market cap.
Risk Factors
- Insider sales can sometimes precede negative news, but the 10b5-1 plan reduces that risk.
- No other material risks identified from this filing alone.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001973379-26-000234 |
| Document: 0001973379-26-000234-index.html | 0001973379-26-000234 |
| Document: 0001973379-26-000234.txt | 0001973379-26-000234 |
Track record
38 reports on QURE
6 of 11 bullish or bearish reports moved the stock their way by T+1. Best: +27.15% at T+20 after the Jul 29, 2026 report. 8 of 11 went positive at some point.
Filters
- Nov 6, 202610d ago 144 Neutral 2/10 Entry $22.79 to $22.71 Now $21.88 −3.99% ▼ −0.35% +0.02% vs SPY
- Nov 4, 202612d ago 8-K Bullish 7/10 No price data
- Nov 4, 202612d ago Press Release Neutral 6/10 Entry $23.03 to $21.01 Now $21.88 −4.99% ▼ −8.77% −4.36% vs SPY
- Nov 2, 202614d ago 8-K Bullish 7/10 Entry $22.97 to $23.87 Now $21.88 −4.75% ▲ +3.92% +3.62% vs SPY
- Nov 2, 202614d ago Press Release Bullish 7/10 Entry $22.97 to $23.87 Now $21.88 −4.75% ▲ +3.92% +3.62% vs SPY
- Oct 16, 20264w ago SC 13G/A Neutral 3/10 Entry $21.78 to $22.20 Now $21.88 +0.46% ▲ +1.93% +1.51% vs SPY
- Sep 2, 202610w ago 8-K Bullish 7/10 Entry $46.23 to $44.86 Now $21.88 −52.67% ▼ −2.96% −4.01% vs SPY
- Jul 29, 202615w ago 8-K Bullish 8/10 Entry $40.07 to $42.19 Now $21.88 −45.40% ▲ +5.29% +3.61% vs SPY
- Jul 7, 202619w ago Insider Cluster Bearish 5/10 Entry $41.41 to $43.49 Now $21.88 +47.16% ▼ −5.02% −5.33% vs SPY
- Jul 2, 202619w ago Insider Cluster Bearish 4/10 Entry $41.81 to $41.36 Now $21.88 +47.67% ▲ +1.08% +1.95% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers